Full Press Release Details
Media
Ironwood Pharmaceuticals is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients.
May 6, 2024
IRWD Positive Sentiment
Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference
Key Takeaway: Ironwood Pharmaceuticals has announced its participation in The Citizens JMP Life Sciences Conference. The company focuses on advancing treatments for gastrointestinal diseases and aims to set new standards of care for patients. This involvement underscores Ironwood's commitment to innovation in the healthcare sector.
Price reaction · baseline $8.12 (2024-05-03 close) · 2 other IRWD headline(s) in the window, move may be shared
day 0 close
-0.1%
Market Sentiment Analysis
POSITIVE FACTORS
- Ironwood Pharmaceuticals is advancing treatment for GI diseases.
- The company aims to redefine the standard of care for GI patients.
- Participation in the conference highlights their commitment to innovation.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+57%
120-day peak, hindsight
Typical move
3.8%
average across 2 past catalysts
Lead asset
IW-3718
Phase 3 · Gastroesophageal Reflux Disease (GERD)
Frequently Asked Questions
What is the focus of Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals specializes in gastrointestinal healthcare.
What conference will Ironwood participate in?
Ironwood will participate in The Citizens JMP Life Sciences Conference.
When is the conference taking place?
The conference is scheduled for May 6, 2024.
What is Ironwood's mission?
Ironwood aims to advance treatments for GI diseases and improve patient care.